The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of In…


LOS ANGELES–()–The Law Offices of Frank R. Cruz continues its investigation on behalf of FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers’ possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On April 6, 2021, after the market closed, FibroGen issued a statement “provid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (‘CKD’).” Specifically, the Company stated that the safety analyses “included post-hoc changes to the…



Click here to view the original article.

S&P/ASX 200 
7,065.60  2.10  0.03%  
ALL ORDINARIES 
7,328.00  2.20  0.03%  
Dow Jones Industrial Average 
34,200.67  164.67  0.48%  
S&P 500 
4,185.47  15.05  0.36%  
NASDAQ Composite 
14,052.34  13.54  0.10%  
NYSE COMPOSITE (DJ) 
16,186.30  69.50  0.43%  
FTSE 100 
7,019.86  0.3301  0.00%  
DAX PERFORMANCE-INDEX 
15,418.09  41.66  0.27%  
Nikkei 225 
29,685.37  2.00  0.01%  
HANG SENG INDEX 
29,106.15  136.44  0.47%